Please login to the form below

Not currently logged in
Email:
Password:

Ardelyx appoints William Bertrand Jr to board of directors

Executive VP of Infinity Pharmaceuticals joins the team
Ardelyx

Ardelyx has appointed William Bertrand Jr to its board of directors.

Ardelyx is a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases.

Bertrand is currently executive VP of general counsel for Infinity Pharmaceuticals and prior to this he served as senior VP and CEO for Salix Pharmaceuticals.

He said: “Ardelyx is uniquely positioned within the life sciences, both in terms of the strength and track record of its senior team, as well as its strategy addressing diseases with substantial unmet needs.”

Mike Raab, president and CEO of Ardelyx, added: “Bill brings extensive experience helping companies growth through early stages of development and into commercialisation.

“His expertise, both operationally and as general counsel, will be of great importance as we continue to accelerate the advancement of our lead programs and develop into a commercial-ready company.”

27th October 2015

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

Article: Like, Like, Like: Harnessing the power of social media insights
...
Its Know Your Numbers week
Do you know yours?...
What is changing in mental health and dementia care?
Paul Midgley, of Wilmington Healthcare, takes a look at the NHS Long Term Plan's bid to transform mental health and dementia services...

Infographics